<code id='9F7222064E'></code><style id='9F7222064E'></style>
    • <acronym id='9F7222064E'></acronym>
      <center id='9F7222064E'><center id='9F7222064E'><tfoot id='9F7222064E'></tfoot></center><abbr id='9F7222064E'><dir id='9F7222064E'><tfoot id='9F7222064E'></tfoot><noframes id='9F7222064E'>

    • <optgroup id='9F7222064E'><strike id='9F7222064E'><sup id='9F7222064E'></sup></strike><code id='9F7222064E'></code></optgroup>
        1. <b id='9F7222064E'><label id='9F7222064E'><select id='9F7222064E'><dt id='9F7222064E'><span id='9F7222064E'></span></dt></select></label></b><u id='9F7222064E'></u>
          <i id='9F7222064E'><strike id='9F7222064E'><tt id='9F7222064E'><pre id='9F7222064E'></pre></tt></strike></i>

          Home / comprehensive / knowledge

          knowledge


          knowledge

          author:leisure time    Page View:31
          Hiram Secrist (left), who has Duchenne muscular dystrophy, with his mother, Kristen Secrist (center), and his grandmother, Terrie Jordan. Courtesy Secrist family

          In mid-July, Kristen Secrist hopped on a call with her 5-year-old son’s doctor, who had urgent news: The first gene therapy had been approved for Duchenne muscular dystrophy. Her son, Hiram, would be a perfect candidate — if, she added, they could get him dosed in time.

          The treatment was approved only for 4- and 5-year-olds. Hiram turned 6 in three weeks. 

          advertisement

          “Oh, crap,” Secrist said to herself.

          Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

          GET STARTED Log In